Bimekizumab for treating moderate to severe chronic plaque psoriasis: A NICE Technology Appraisal
Bimekizumab for treating moderate to severe chronic plaque psoriasis: A NICE Technology Appraisal
This report is a critique of the company’s submission to the NICE Fast Track Appraisal programme of a cost comparison of bimekizumab for treating moderate to severe plaque psoriasis.
National Institute for Health and Care Research
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
2021
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Hazell, Lorna, Lord, Joanne, Kalita, Neelam, Scott, David Alexander and Shepherd, Jonathan
(2021)
Bimekizumab for treating moderate to severe chronic plaque psoriasis: A NICE Technology Appraisal
(Health Technology Assessment, HTA - NIHR133179)
Southampton.
National Institute for Health and Care Research
35pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission to the NICE Fast Track Appraisal programme of a cost comparison of bimekizumab for treating moderate to severe plaque psoriasis.
Text
Bimekizumab ERG report
Restricted to Repository staff only
Request a copy
More information
Published date: 2021
Identifiers
Local EPrints ID: 454185
URI: http://eprints.soton.ac.uk/id/eprint/454185
PURE UUID: f232b28a-3285-451a-9e60-5ae4a51007b4
Catalogue record
Date deposited: 01 Feb 2022 18:08
Last modified: 11 Sep 2024 02:26
Export record
Contributors
Author:
David Alexander Scott
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics